# Pharmacyclics LLC. clinical trials: 54 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 54 trials with Pharmacyclics LLC. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Pharmacyclics LLC.: 54 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/pharmacyclics-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 54
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 54, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| December 31, 2018 | NCT03790332 | Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) | Pharmacyclics LLC. | Phase 1/2 | Completed | Chronic Graft Versus Host Disease | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03790332) |
| April 13, 2017 | NCT03112174 | Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL) | Pharmacyclics LLC. | Phase 3 | Completed | Mantle-Cell Lymphoma | 366 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03112174) |
| November 9, 2016 | NCT02959944 | Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft... | Pharmacyclics LLC. | Phase 3 | Completed | Chronic Graft Versus Host Disease | 193 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02959944) |
| October 27, 2016 | NCT02947347 | Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma | Pharmacyclics LLC. | Phase 3 | Completed | Follicular Lymphoma | 445 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02947347) |
| September 22, 2016 | NCT02910583 | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) | Pharmacyclics LLC. | Phase 2 | Completed | Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 323 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02910583) |
| November 6, 2015 | NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | Pharmacyclics LLC. | Phase 1/2 | Completed | Metastatic Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Colorectal... | 263 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02599324) |
| October 21, 2015 | NCT02582879 | informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia | Pharmacyclics LLC. | Observational | Completed | Chronic Lymphocytic Leukemia (CLL) | 1,504 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02582879) |
| September 14, 2015 | NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | Pharmacyclics LLC. | Phase 1/2 | Terminated | Multiple Myeloma | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02548962) |
| May 7, 2015 | NCT02436668 | Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic... | Pharmacyclics LLC. | Phase 3 | Completed | Metastatic Pancreatic Adenocarcinoma | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02436668) |
| March 31, 2015 | NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | Pharmacyclics LLC. | Phase 1/2 | Completed | Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02403271) |
| March 27, 2015 | NCT02401048 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas | Pharmacyclics LLC. | Phase 1/2 | Completed | Diffuse Large B-Cell Lymphoma, Follicular Lymphoma | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02401048) |
| January 30, 2015 | NCT02351037 | Study of Ibrutinib in Subjects With Acute Myeloid Leukemia | Pharmacyclics LLC. | Phase 2 | Terminated | Acute Myeloid Leukemia (AML) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02351037) |
| October 15, 2014 | NCT02264574 | A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With... | Pharmacyclics LLC. | Phase 3 | Completed | Chronic Lymphocytic Leukemia, Small-Cell Lymphoma | 229 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02264574) |
| July 21, 2014 | NCT02195869 | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease | Pharmacyclics LLC. | Phase 1/2 | Completed | Graft Versus Host Disease | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02195869) |
| June 17, 2014 | NCT02165397 | Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | Pharmacyclics LLC. | Phase 3 | Completed | Waldenström's Macroglobulinemia | 181 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02165397) |
| May 20, 2014 | NCT02142049 | Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Pharmacyclics LLC. | Phase 1/2 | Completed | Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02142049) |
| March 4, 2014 | NCT02077166 | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Pharmacyclics LLC. | Phase 1/2 | Completed | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02077166) |
| November 11, 2013 | NCT01980654 | Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma | Pharmacyclics LLC. | Phase 2 | Completed | Follicular Lymphoma, B-cell Lymphoma, Non-Hodgkin's Lymphoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01980654) |
| November 11, 2013 | NCT01980628 | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma | Pharmacyclics LLC. | Phase 2 | Completed | Marginal Zone Lymphoma, B-cell Lymphoma | 63 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01980628) |
| October 14, 2013 | NCT01962792 | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | Pharmacyclics LLC. | Phase 1/2 | Completed | Multiple Myeloma | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01962792) |
| December 7, 2012 | NCT01744691 | A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic... | Pharmacyclics LLC. | Phase 2 | Completed | Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion | 145 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01744691) |
| November 9, 2012 | NCT01724346 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Pharmacyclics LLC. | Phase 3 | Completed | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 269 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01724346) |
| November 6, 2012 | NCT01722487 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | Pharmacyclics LLC. | Phase 3 | Completed | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 269 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01722487) |
| April 17, 2012 | NCT01578707 | A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Pharmacyclics LLC. | Phase 3 | Completed | Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 391 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01578707) |
| November 23, 2011 | NCT01478581 | Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma | Pharmacyclics LLC. | Phase 2 | Completed | Multiple Myeloma | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01478581) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 10 |
| Phase 1/2 | 13 |
| Phase 2 | 19 |
| Phase 3 | 11 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 46 |
| Terminated | 8 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Leukemia, Lymphocytic, Chronic, B-Cell | 15 |
| Lymphoma | 11 |
| Lymphoma, Non-Hodgkin | 11 |
| Lung Neoplasms | 8 |
| Lymphoma, B-Cell | 7 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Lymphoma, Follicular | 6 |
| Leukemia | 6 |
| Multiple Myeloma | 6 |
| Bronchiolitis Obliterans Syndrome | 5 |
| Neoplasm Metastasis | 5 |
| Lymphoma, Mantle-Cell | 5 |
| Lymphoma, Large B-Cell, Diffuse | 4 |
| Leukemia, Lymphoid | 4 |
| Leukemia, B-Cell | 4 |
| Brain Neoplasms | 4 |
| Breast Neoplasms | 4 |
| Graft vs Host Disease | 3 |
| Kidney Neoplasms | 3 |
| Neoplasms | 3 |
| Waldenstrom Macroglobulinemia | 3 |
| Hodgkin Disease | 3 |
| Lymphoma, B-Cell, Marginal Zone | 3 |
| Pancreatic Neoplasms | 3 |
| Glioblastoma | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Shared office spaces in the United States](https://specstream.ai/data/businesses/shared-office-spaces/united-states)
- [Banks in the United States](https://specstream.ai/data/businesses/banks/united-states)
- [Freight forwarders in the United States](https://specstream.ai/data/businesses/freight-forwarders/united-states)
- [Pediatric nephrology practices in the United States](https://specstream.ai/data/businesses/pediatric-nephrology-practices/united-states)
- [Wholesalers in the United States](https://specstream.ai/data/businesses/wholesalers/united-states)
- [Dental supply stores in the United States](https://specstream.ai/data/businesses/dental-supply-stores/united-states)
